Search results for "METASTASIS"

showing 10 items of 986 documents

The Fuhrman grading system has no prognostic value in patients with nonsarcomatoid chromophobe renal cell carcinoma.

2014

The prognostic value of the Fuhrman nuclear grading system has been questioned for chromophobe renal cell carcinoma (chRCC) because this subtype frequently displays nuclear and nucleolar pleomorphism. The present study reevaluates this grading system in a series of patients with nonsarcomatoid chRCC. We identified 176 patients (3.6%) with nonsarcomatoid chRCC in a total of 4897 patients who underwent surgery for renal cell carcinoma at 5 centers in Germany between 1990 and 2010. The mean follow-up was 51.1 months. The 3 groups (G1 versus G2 versus G3/4) were comparable in terms of age, sex, tumor diameter, and lymph node metastasis. They only differed significantly in tumor stage (P = .01) …

OncologyMalemedicine.medical_specialtyChromophobe Renal Cell CarcinomaUrologyPathology and Forensic MedicineRenal cell carcinomaInternal medicineMedicineHumansSurvival rateCarcinoma Renal CellRetrospective StudiesNeoplasm Gradingbusiness.industryHistologyRetrospective cohort studyMiddle Agedmedicine.diseasePrognosisKidney NeoplasmsSurvival RatePleomorphism (cytology)Lymphatic MetastasisCohortFemaleNeoplasm GradingbusinessHuman pathology
researchProduct

Epidemiology and prognosis of synchronous and metachronous colon cancer metastases: a French population-based study.

2014

Epidemiological data on synchronous and metachronous metastatic colon cancer are scarce. We assessed epidemiological characteristics and survival in synchronous and metachronous metastatic colon cancer in a French population.Our study included 932 cases of metastatic colon cancer diagnosed in 1999-2010 and registered in a population-based cancer registry; 758 were synchronous colon metastases and 174 metachronous metastases from resected primary colon cancers diagnosed in 1999-2005. Univariate relative survival was calculated and a multivariate model with proportional hazard applied to net survival by interval was used.Mean age at diagnosis was 71.1 years for patients with metachronous meta…

OncologyMalemedicine.medical_specialtyColorectal cancermedicine.medical_treatmentPopulationNeoplasms Multiple PrimaryMetachronous metastasisRisk FactorsInternal medicineEpidemiologyMedicineHumanseducationAgedRetrospective StudiesChemotherapyeducation.field_of_studyHepatologyRelative survivalbusiness.industryGastroenterologyNeoplasms Second PrimaryOdds ratiomedicine.diseasePrognosisCancer registrySurvival RatePopulation SurveillanceColonic NeoplasmsFemaleFranceMorbiditybusinessFollow-Up StudiesDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Squamous Cell Carcinoma: Clinical and Pathological Features and Associated Risk Factors in an Observational Study of 118 Patients

2015

Background and objective: In the latest edition of its cancer staging manual, the American JointCommittee on Cancer (AJCC) revised the criteria for staging squamous cell carcinoma (SCC) by introducing high-risk tumor features to define tumor stage (T) and help to identify tumors with a higher risk of metastasis. The aim of this study was to investigate the characteristics associated with SCC meeting the high-risk criteria defined by the AJCC for T2 lesions. Patients and method: We performed a case-case observational study in which patients with SCC were included over a period of 18 months. We collected clinical, anthropometric, and tumor data, and analyzed these using PASW Statistics (SPSS)…

OncologyMalemedicine.medical_specialtyHistologyNeoplasms Radiation-InducedSkin NeoplasmsCumulative ExposureSkin PigmentationDermatologyComorbidityPathology and Forensic MedicineMetastasisRisk FactorsInternal medicinemedicineHumansPathologicalCancer stagingAgedNeoplasm StagingGynecologyAged 80 and overAnthropometrybusiness.industrySmokingAge FactorsCancerOdds ratiomedicine.diseaseComorbidityTumor BurdenKeratosis ActinicHead and Neck NeoplasmsSpainCarcinoma Squamous CellObservational studyFemalebusiness
researchProduct

Cancer Stem Cells Sensitivity Assay (STELLA) in Patients with Advanced Lung and Colorectal Cancer: A Feasibility Study.

2015

Background Cancer stem cells represent a population of immature tumor cells found in most solid tumors. Their peculiar features make them ideal models for studying drug resistance and sensitivity. In this study, we investigated whether cancer stem cells isolation and in vitro sensitivity assay are feasible in a clinical setting. Methods Cancer stem cells were isolated from effusions or fresh cancer tissue of 23 patients who progressed after standard therapy failure. Specific culture conditions selected for immature tumor cells that express markers of stemness. These cells were exposed in vitro to chemotherapeutic and targeted agents. Results Cancer stem cells were extracted from liver metas…

OncologyMalemedicine.medical_specialtyLung NeoplasmsTime FactorsColorectal cancerTarget therapy drug sensitivity cancer stem cellsPopulationlcsh:MedicineAntineoplastic AgentsDrug resistanceCell SeparationCancer stem cellInternal medicinemedicineHumansIn patienteducationlcsh:ScienceAgedAged 80 and overSettore MED/04 - Patologia Generaleeducation.field_of_studyMultidisciplinaryLungbusiness.industrylcsh:RLiver NeoplasmsMiddle Agedmedicine.diseaseIn vitroClinical trialPleural EffusionDrug Combinationsmedicine.anatomical_structureLymphatic MetastasisNeoplastic Stem CellsFeasibility Studieslcsh:QFemaleDrug Screening Assays AntitumorbusinessColorectal NeoplasmsResearch Article
researchProduct

Risk estimation for biliary tract cancer: Development and validation of a prognostic score.

2017

Background & Aims Biliary tract cancer is a rare tumour entity characterized by a poor prognosis. We aimed to identify prognostic factors and create a prognostic score to estimate survival. Methods Clinical data of the training set, consisting of 569 patients treated from 2000 to 2010 at Hannover Medical School, were analysed. A prognostic model defining three prognostic risk groups was derived from Cox regression analyses. The score was applied and validated in an independent cohort of 557 patients from four different German centres. Results Median overall survival (OS) was 14.5 months. If complete resection was performed, the patients had a significantly improved OS (23.9 months; n=242) a…

OncologyMalemedicine.medical_specialtyRisk AssessmentPrognostic scoreMetastasisCholangiocarcinomaCohort Studies03 medical and health sciences0302 clinical medicineInternal medicineGermanymedicineHumansAgedBiliary tract neoplasmBiliary tract cancerHepatologybusiness.industryProportional hazards modelMiddle Agedmedicine.diseasePrognosisSurgeryBiliary Tract Neoplasms030220 oncology & carcinogenesisCohort030211 gastroenterology & hepatologyFemaleRisk assessmentbusinessCohort studyLiver international : official journal of the International Association for the Study of the Liver
researchProduct

Molecular target therapy for bone metastasis : starting a new era with denosumab, a RANKL inhibitor

2014

Abstract: Introduction: The skeleton is generally the primary, and sometimes the only, site of metastasis in patients with advanced solid tumors. Bone metastases are the most frequent cause of cancer-related pain and the origin of severe morbidity in patients. Among the treatment options available for the prevention of skeletal-related events (SREs) associated with bone metastasis, zoledronic acid, an antiresorptive treatment from the group of bisphosphonates, is currently the standard of care in this setting. Areas covered: Zoledronic acid, together with denosumab (a monoclonal antibody against the receptor activator of nuclear factor kappa B ligand), is the most frequent approach for the …

OncologyMalemedicine.medical_specialtySettore MED/06 - Oncologia MedicaClinical BiochemistryAntineoplastic AgentsBone NeoplasmsAntibodies Monoclonal HumanizedZoledronic AcidMetastasisProstate cancerBreast cancerInternal medicineDrug DiscoverymedicineAnimalsHumansMolecular Targeted TherapyBiologyPharmacologyDiphosphonatesbusiness.industrybone metastasis breast cancer denosumab prostate cancer skeletal-related events solid tumorsRANK LigandImidazolesBone metastasismedicine.diseaseSurgeryZoledronic acidDenosumabTreatment OutcomeMonoclonalPractice Guidelines as TopicHuman medicineDenosumabbusinessRANKL InhibitorEngineering sciences. Technologymedicine.drugExpert opinion on biological therapy
researchProduct

Prognostic Impact of pT Stage and Peritoneal Invasion in Locally Advanced Colon Cancer

2019

BACKGROUND: TNM stage has been identified as an independent variable for local recurrence and survival after colon cancer resection. It is still unclear whether peritoneal invasion (pT4a) is a risk factor for adverse oncologic outcome or whether these patients have better results compared with contiguous organs infiltration (pT4b), independent from nodal status (pN). OBJECTIVE: The purpose of this study was to analyze whether peritoneal invasion is an independent risk factor for worse oncologic outcome after curative colon cancer resection. DESIGN: This was a retrospective analysis with multivariate regression of a prospective database, according to Strengthening the Reporting of Observatio…

OncologyMalemedicine.medical_specialtySurvivalColorectal cancermedicine.medical_treatmentLocally advancedT stageLocally advanced colon cancer03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineColon cancer resectionHumansNeoplasm InvasivenessRisk factorStage (cooking)Survival rateColectomyPeritoneal NeoplasmsColectomyAgedNeoplasm StagingRetrospective StudiesCarcinomatosisTumor-node-metastasisbusiness.industryGastroenterologyRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseasePrognosisColon cancerSurvival RateTreatment Outcome030220 oncology & carcinogenesisColonic Neoplasms030211 gastroenterology & hepatologyFemaleNeoplasm Recurrence Localbusiness
researchProduct

Nivolumab in metastatic melanoma: good efficacy and tolerability in elderly patients.

2020

Nivolumab is an anti&ndash

OncologyMalemedicine.medical_specialtymedicine.medical_treatmentT cellelderly patients03 medical and health sciences0302 clinical medicineImmune systemmelanoma metastaticAntineoplastic Agents ImmunologicalInternal medicinemedicineHumans030212 general & internal medicineNeoplasm MetastasisMelanomaAgedbiologybusiness.industryMelanomaclinical benefitlactate dehydrogenaseImmunotherapymedicine.diseaseConfidence intervalelderly patientmedicine.anatomical_structureNivolumabTolerability030220 oncology & carcinogenesisbiology.proteinQuality of LifeFemaleOriginal ArticleImmunotherapyNivolumabAntibodybusinessCurrent oncology (Toronto, Ont.)
researchProduct

Predicting survival in node-positive prostate cancer after open, laparoscopic or robotic radical prostatectomy: A competing risk analysis of a multi-…

2016

Objectives: To investigate cancer-specific mortality and other-cause mortality in prostate cancer patients with nodal metastases. Methods: The study included 411 patients treated with radical prostatectomy and pelvic lymph node dissection for prostate cancer with lymph node metastases at 10 tertiary care centers between 1995 and 2014. Kaplan–Meier analyses were used to assess cancer-specific mortality-free survival rates at 8 years' follow up in the overall population, and after stratifying patients according to clinical and pathological parameters. Uni- and multivariable competing risk Cox regression analyses were used to assess cancer-specific mortality and other-cause mortality. Finally,…

OncologyMalemedicine.medical_treatment030232 urology & nephrologyProstate cancer0302 clinical medicineRobotic Surgical ProceduresLymph nodeeducation.field_of_studyProstatectomyMortality rateLymph NodePrognosiscancer-specific mortality competing risk analysis lymph node metastases other-cause mortality radical prostatectomylymph node metastaseDissectionmedicine.anatomical_structure030220 oncology & carcinogenesisLymphatic MetastasisLymphSurvival Analysicancer-specific mortality; competing risk analysis; lymph node metastases; other-cause mortality; radical prostatectomycancer-specific mortality; competing risk analysis; lymph node metastases; other-cause mortality; radical prostatectomy; Urologyother-cause mortalityHumanlymph node metastasesRiskmedicine.medical_specialtyRobotic Surgical ProcedurePrognosiUrologyPopulationUrologycancer-specific mortality03 medical and health sciencesInternal medicinemedicineHumanseducationcompeting risk analysiProstatectomybusiness.industryProportional hazards modelcompeting risk analysisProstatic NeoplasmsLymphatic MetastasiProstate-Specific Antigenmedicine.diseaseSurvival Analysisradical prostatectomyProstatic NeoplasmLymph Node ExcisionLaparoscopyLymph Nodesbusiness
researchProduct

Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable res…

2021

Programa para el Tratamiento de Hemopatias Malignas (PETHEMA) Group (Spanish Society of Hematology, SEHH).

OncologyMalep13)/TCF3-PBX1Neoplasm ResidualOncogene Proteins FusionCytogenetic alterationsmedicine.medical_treatmentDiseaseTranslocation Genetichemic and lymphatic diseasesAntineoplastic Combined Chemotherapy Protocolst(1;19)(q23;p13)/TCF3-PBX1Cumulative incidenceCitogenètica humanaNeoplasm MetastasisLeucèmia limfoblàstica - TractamentHuman cytogeneticsLeukemiaAcute lymphoblastic leukaemiaRemission InductionLeucèmiaDisease ManagementHematologyMiddle AgedPrognosisHaematopoiesismedicine.anatomical_structureTreatment OutcomeChromosomes Human Pair 1TCF3:Other subheadings::Other subheadings::/therapy [Other subheadings]FemaleStem cell:Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia Lymphoid::Precursor Cell Lymphoblastic Leukemia-Lymphoma::Precursor B-Cell Lymphoblastic Leukemia-Lymphoma [DISEASES]Adultmedicine.medical_specialtyPronòstic mèdicAdolescentQuimioteràpia combinadaYoung AdultInternal medicinePrecursor B-Cell Lymphoblastic Leukemia-LymphomamedicineAdultsHumansB cell19)(q23Neoplasm Staging:neoplasias::neoplasias por tipo histológico::leucemia::leucemia linfoide::leucemia-linfoma linfoblástico de células precursoras::leucemia-linfoma linfoblástico de células B precursoras [ENFERMEDADES]business.industryacute lymphoblastic leukaemia adults cytogenetic alterations prognosis t(1:Otros calificadores::Otros calificadores::/terapia [Otros calificadores]ImmunotherapyChromosome BandingTransplantationt(1Avaluació de resultats (Assistència sanitària)businessChromosomes Human Pair 19British journal of haematologyReferences
researchProduct